Colorectal Cancer Vaccines

Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against colorectal cancer and guarantee the finest results for our customers all over the world.

Colorectal Cancer

Colorectal cancer (CRC), also known as colon cancer and bowel cancer, is a type of cancer arising from the colon or rectum (part of the large intestine). Most colorectal cancers are due to aging and lifestyle factors and only a minority of cases are due to underlying genetic disorders. Some of the risk factors include smoking, obesity, diet and lack of exercise. Another risk factor is inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Signs and symptoms may include feeling of tiredness, weight loss, and blood in the stool. It usually starts with a benign tumor, usually in the form of polyps, and becomes cancerous over time. Colonoscopy can be diagnosed by taking a colon sample during sigmoidoscopy or colonoscopy. Medical imaging is then performed to determine if the disease has spread. Treatments for colorectal cancer may include some combination of surgery, radiotherapy, chemotherapy and targeted therapies.

Therapeutic Vaccines for Colorectal Cancer

Colorectal Cancer - Creative Biolabs

In a multicenter study of patients with metastatic CRC, 77 patients received a synthetic vaccine targeting beta-human chorionic gonadotropin (B-HCG). The vaccine contained a COOH-terminal peptide of the B-HCG (CTP37) conjugated with diphtheria toxoid (DT). The median survival for patients who demonstrated anti-HCG antibody levels greater than or equal to the median value was 45 weeks, compared with 24 weeks for patients with antibody levels lower than the median value. DT antibody levels did not have an impact on survival. In a phase II multicenter study, G17DT, a human immunogen that stimulates antibody production against the growth factor gastrin 17, was administered in combination with irinotecan to patients with metastatic CRC refractory to irinotecan. Survival for anti-G17 responders (based on antibody titers) was 9 months, significantly longer than 5.6 months for nonresponders. In a phase III prospective randomized trial, 80 eligible patients with CRC were treated with either resection and autologous tumor cell-BCG vaccine or resection alone. A significant survival benefit was noted in colon cancer patients who received BCG, but not in rectal cancer patients who received BCG. A phase III trial using ATV-NDV (Newcastle disease virus-infected intact autologous tumor cell vaccine) in patients after complete resection of colorectal liver metastases demonstrated that ATV-NDV was beneficial in prolonging overall and metastasis-free survival in colon cancer patients, but not in rectal cancer patients.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the colorectal cancer vaccines. If you are interested in our services, please contact us for more details.


Our services are for research use only. We do not provide services directly to individuals.

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Project Description:
*Verification Code:
Verification code
Click image to refresh the verification code.

CONTACT US

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:


Follow us on

facebook   twitter   linked   blog

Shopping Basket